Targeted cancer prevention programs are available for confirmed carriers of pathogenic gene variants associated with hereditary breast and ovarian cancer (BRCA1, BRCA2, PALB2) or Lynch syndrome (MLH1, MSH2, MSH6, PMS2). The gene discussed is PMS2; the disease is Hereditary breast and ovarian cancer syndrome.